Next on tap for Meridian Bioscience‘s (NASDAQ:VIVO) illumigene molecular diagnostic testing platform is a test for Mycoplasma pneumonia, an infection of the lungs. The illumigene Mycoplasma test is ...
CINCINNATI, Ohio — Meridian Bioscience’s European division will distribute in Italy a test for intestinal problems with plans to expand into France. The test, Quantum Blue Calprotectin, differentiates ...
CINCINNATI, July 23, 2021 (GLOBE NEWSWIRE) -- Meridian Bioscience, Inc., a leading global provider of diagnostic testing solutions and life science raw materials, announced today that it signed a ...
Meridian Bioscience, Inc.: Magellan Diagnostics, Inc. Expands Voluntary Recall of LeadCare Test Kits
Customers should discontinue use of all LeadCare Test Kits lots identified as part of the recall and quarantine remaining inventory. Distributors should stop distribution of all LeadCare Test Kits ...
CINCINNATI, Aug. 09, 2017 (GLOBE NEWSWIRE) -- Meridian Bioscience, Inc. (NASDAQ:VIVO) today announced that it has initiated clinical trials for a new illumigene CMV molecular amplification test. This ...
(Reuters) - Meridian Bioscience Inc said its test to detect a common bacterial throat infection received marketing approval in the United States. Meridian said its molecular test can detect Group A ...
Meridian Bioscience (NASDAQ:VIVO) announced on Wednesday that the company’s wholly-owned subsidiary, Magellan Diagnostics, expanded the voluntary recall of LeadCare test kits. With the decision, the ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback